Why the study?
Does intravenous dipyridamole testing accurately predict critical coronary stenoses in patients with chest pain?
Does intravenous dipyridamole testing accurately predict critical coronary stenoses in patients with chest pain?
Intravenous dipyridamole testing demonstrates poor sensitivity and specificity, indicating it cannot be reliably used to predict critical coronary stenoses in patients with chest pain.
Answers are grounded in this paper and cite their sources.
Warrants caution against dipyridamole testing for stenosis prediction; leaves open validation of superior noninvasive strategies.
In order to assess the diagnostic value of dipyridamole (D) testing, we studied the responses of 34 patients with chest pain and 10 normal subjects. Blood pressure and 12-lead ECG were recorded during and after intravenous infusion of 0.6 mg/kg dipyridamole for 10 minutes. Coronary arteriography and maximal or symptom-limited exercise tests were performed in the 34 patients with chest pain. During infusion 13 patients presented ischemic ST changes and 5 with anginal pain only. The latter group had normal coronary arteries. Among the 13 patients with ischemic ST changes, 7 had at least two critical coronary stenoses and the remaining 6 had no coronary lesions. Dipyridamole tests showed poor sensitivity (44%) and specificity (39%) with respect to coronary arteriography. The relatively high number of positive responses in subjects with normal coronary arteries indicates that the coronary steal phenomenon is not the sole cause of "ischemic" response to the drug. Indirect indexes of myocardial oxygen consumption were higher in patients with a positive response to drug infusion than in those with a negative response; however the value of rate-pressure product at infusion end never reached that observed at ischemic threshold during exercise testing in the same patient. This suggests that neither can oxygen consumption increase be considered as entirely responsible for ischemic response to dipyridamole. In conclusion dipyridamole test cannot be proposed for predicting critical coronary stenoses.
No takes yet. Share an insight, caveat, or question.
Deambroggi et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: